论文部分内容阅读
目的探讨拉米夫定联合水飞蓟滨对治疗乙型肝炎肝硬化指标变化的影响。方法将64例乙型肝炎肝硬化患者随机分为治疗组和对照组,治疗最少12个月,在治疗前、治疗后半年及治疗前、治疗后12个月测定肝纤维化指标及肝功能指标,进行相关性比较分析。结果治疗组肝纤维化及肝功能指标下降明显优于对照组,差异具有统计学意义(P<0.05);同时其AST治疗组1年后与半年后比较AST下降明显,其疗效与疗程呈相关性。结论拉米夫定联合水飞蓟滨能明显改善乙肝肝硬化患者肝纤维化指标及肝功能指标。
Objective To investigate the effect of lamivudine and silybin on the treatment of hepatitis B cirrhosis. Methods Sixty-four patients with hepatitis B cirrhosis were randomly divided into treatment group and control group, with a minimum of 12 months treatment. Liver fibrosis indexes and liver function indexes were measured before treatment, six months after treatment, before treatment and 12 months after treatment , Comparative analysis of the correlation. Results The decrease of hepatic fibrosis and liver function in the treatment group was significantly better than that in the control group (P <0.05). At the same time, AST in the AST treatment group decreased significantly after one year and six months later, and the curative effect was correlated with the course of treatment Sex. Conclusions Lamivudine combined with silymarin can significantly improve hepatic fibrosis and liver function in patients with hepatitis B cirrhosis.